Orion Group Holdings, Inc. (NYSE: ORN ) faced some headwinds going into the close of Q2 ’25 with the expectation of multiple large project proposals being pushed out to Q3 ’25. Despite the near-term headwinds, Orion hasMonte Independent Investment Research: Michael Del Monte is a buy-side equity analyst with over 5 years of industry experience. Prior to working in the investment management industry, Michael spent over a decade in professional services working across industries that include O&G, OFS, Midstre ...

Market Impact of Geopolitical Events - Oil price spikes due to geopolitical events are typically short-lived, unless a major disruption like the closure of the Straits of Hormuz occurs [2] - Protracted geopolitical conflicts could lead to lower yields due to a flight to quality and a stronger dollar, but are generally not market-friendly [3] - A "flight to safety" is more accurate than a "flight to quality" in the current environment, with US Treasuries and the US dollar being the beneficiaries [4] - Market participants were previously concerned about a weak dollar and higher 10-year yields [5] Investment Opportunities - Past geopolitical events have often presented buying opportunities, depending on the market discount offered [6] - The current situation is viewed as a potential buying opportunity, barring a major escalation like World War II [6] - Companies involved in drone warfare and arsenal buildup, such as Northrup Grumman (NOC) and Kratos, may present investment opportunities [7][8] - The market dip is considered a buying opportunity [10][11] Market Indicators - The 10-year yield has decreased from 445 basis points to 433 basis points [5] - The VIX is not expected to remain at its current level of 21, and is likely to either increase significantly or gradually decline [10] - The dollar has only increased by a small amount over the last few trading days [5]

Core Insights - Iovance Biotherapeutics experienced a significant stock decline on May 9 following a disappointing first-quarter earnings report, with a loss of $0.36 per share compared to the consensus estimate of a $0.24 loss [1] - The company's revenue for Q1 was reported at $49.3 million, which fell short of the expected $81.53 million [1] Financial Performance - The earnings per share (EPS) loss of $0.36 indicates a larger loss than analysts had anticipated [1] - Revenue of $49.3 million represents a substantial shortfall from the forecasted revenue of $81.53 million, highlighting potential operational challenges [1]

Company Overview - Pro-Dex, Inc. (PDEX) is a contract manufacturer focused on designing, developing, and manufacturing surgical devices for the medical device industry [1] - The stock has experienced significant volatility over the past year, trading between a high of $70 and a low of $16 [1] Performance Insights - The company has achieved record performance, although specific metrics or figures are not provided in the text [1]